دورية أكاديمية
Role of Dexamethasone and Methylprednisolone Corticosteroids in Coronavirus Disease 2019 Hospitalized Patients: A Review.
| العنوان: | Role of Dexamethasone and Methylprednisolone Corticosteroids in Coronavirus Disease 2019 Hospitalized Patients: A Review. |
|---|---|
| المؤلفون: | Mehta J; Faculty of Applied Sciences and Biotechnology, Shoolini University of Biotechnology and Management Sciences, Solan, India., Rolta R; Faculty of Applied Sciences and Biotechnology, Shoolini University of Biotechnology and Management Sciences, Solan, India., Mehta BB; Department of Immunology, University Institute of Oslo, Oslo, Norway., Kaushik N; Department of Biotechnology, The University of Suwon, Hwaseong, South Korea., Choi EH; Department of Electrical and Biological Physics, Plasma Bioscience Research Center, Kwangwoon University, Seoul, South Korea., Kaushik NK; Department of Electrical and Biological Physics, Plasma Bioscience Research Center, Kwangwoon University, Seoul, South Korea. |
| المصدر: | Frontiers in microbiology [Front Microbiol] 2022 Feb 15; Vol. 13, pp. 813358. Date of Electronic Publication: 2022 Feb 15 (Print Publication: 2022). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation Country of Publication: Switzerland NLM ID: 101548977 Publication Model: eCollection Cited Medium: Print ISSN: 1664-302X (Print) Linking ISSN: 1664302X NLM ISO Abbreviation: Front Microbiol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Lausanne : Frontiers Research Foundation |
| مستخلص: | The WHO announced coronavirus disease 2019 (COVID-19) as a pandemic disease globally on March 11, 2020, after it emerged in China. The emergence of COVID-19 has lasted over a year, and despite promising vaccine reports that have been produced, we still have a long way to go until such remedies are accessible to everyone. The immunomodulatory strategy has been kept at the top priority for the research agenda for COVID-19. Corticosteroids have been used to modulate the immune response in a wide range of diseases for the last 70 years. These drugs have been shown to avoid and reduce inflammation in tissues and the bloodstream through non-genomic and genomic effects. Now, the use of corticosteroids increased the chance of survival and relief by combating the viral strong inflammatory impacts and has moved to the forefront in the management of patients seeking supplemental oxygen. The goal of this review is to illuminate dexamethasone and methylprednisolone, i.e., in terms of their chemical and physical properties, role in COVID-19 patients suffering from pneumonia, the proposed mode of action in COVID-19, pharmacokinetics, pharmacodynamics, clinical outcomes in immunocompromised populations with COVID-19, interaction with other drugs, and contradiction to explore the trends and perspectives for future research. Literature was searched from scientific databases such as Science Direct, Wiley, Springer, PubMed, and books for the preparation of this review. The RECOVERY trial, a massive, multidisciplinary, randomized, and open-label trial, is mainly accountable for recommendations over the usage of corticosteroids in COVID-19 patients. The corticosteroids such as dexamethasone and methylprednisolone in the form of medication have anti-inflammatory, analgesic, and anti-allergic characteristics, including the ability to inhibit the immune system. These drugs are also recommended for treating symptoms of multiple ailments such as rheumatic and autoimmune diseases, leukemia, multiple myeloma, and Hodgkin's and non-Hodgkin's lymphoma along with other drugs. Toxicology studies proved them safe usually at low dosage via oral or other routes. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Mehta, Rolta, Mehta, Kaushik, Choi and Kaushik.) |
| References: | J Pharmacol Exp Ther. 1996 Apr;277(1):105-12. (PMID: 8613906) Respir Care. 2018 Jun;63(6):655-670. (PMID: 29794202) Cochrane Database Syst Rev. 2016 Mar 07;3:CD010406. (PMID: 26950335) Clin Microbiol Infect. 2020 Sep;26(9):1171-1177. (PMID: 32603802) Allergy. 2007 Feb;62(2):184-9. (PMID: 17298428) Eur J Clin Pharmacol. 1986;30(3):323-9. (PMID: 3732369) J Infect Dis. 2020 Oct 1;222(9):1444-1451. (PMID: 32601708) N Engl J Med. 2021 Feb 25;384(8):693-704. (PMID: 32678530) Clin Chem. 1974 Feb;20(2):266-71. (PMID: 4855888) Ann N Y Acad Sci. 1959 Oct 14;82:846-53. (PMID: 14432261) Nat Rev Nephrol. 2015 Jan;11(1):46-61. (PMID: 25421826) J Emerg Nurs. 2015 Nov;41(6):470-3. (PMID: 26296715) Science. 1995 Oct 13;270(5234):283-6. (PMID: 7569975) Semin Arthritis Rheum. 2003 Jun;32(6):370-7. (PMID: 12833245) Mil Med Res. 2020 Mar 13;7(1):11. (PMID: 32169119) Clin Rheumatol. 2014 Dec;33(12):1695-706. (PMID: 24651914) N Engl J Med. 2020 Feb 20;382(8):727-733. (PMID: 31978945) Front Immunol. 2020 Jul 23;11:1467. (PMID: 32849503) Eur J Clin Invest. 2020 Nov;50(11):e13412. (PMID: 32954492) Front Immunol. 2019 Jul 04;10:1545. (PMID: 31333672) JAMA. 2020 Mar 17;323(11):1061-1069. (PMID: 32031570) J Clin Endocrinol Metab. 2010 Sep;95(9):4133-60. (PMID: 20823466) J Pharmacokinet Biopharm. 1981 Feb;9(1):1-14. (PMID: 7229914) Eur J Clin Invest. 2021 Feb;51(2):e13458. (PMID: 33219551) Nat Rev Immunol. 2017 Apr;17(4):233-247. (PMID: 28192415) Clin Pharmacol Ther. 2019 Jul;106(1):164-173. (PMID: 30924921) Ocul Immunol Inflamm. 2012 Apr;20(2):91-9. (PMID: 22409561) Lancet. 2020 Feb 29;395(10225):683-684. (PMID: 32122468) Clin Infect Dis. 2021 May 4;72(9):e367-e372. (PMID: 32772069) Wound Repair Regen. 2013 Jan-Feb;21(1):88-102. (PMID: 23126666) PLoS Med. 2006 Sep;3(9):e343. (PMID: 16968120) BMJ. 2006 Mar 4;332(7540):525-7. (PMID: 16513709) Biomed Pharmacother. 2020 Aug;128:110267. (PMID: 32410772) Crit Care Explor. 2020 Jun 15;2(6):e0145. (PMID: 32696008) J Rheumatol. 2006 Jul;33(7):1431-4. (PMID: 16724371) BMJ. 2020 Feb 19;368:m606. (PMID: 32075786) Signal Transduct Target Ther. 2020 Apr 28;5(1):57. (PMID: 32341331) Biomedicines. 2021 Oct 05;9(10):. (PMID: 34680519) Science. 2020 May 1;368(6490):473-474. (PMID: 32303591) Clin Pharmacol Ther. 1975 Aug;18(2):205-9. (PMID: 1097154) BMJ Open Respir Res. 2020 Sep;7(1):. (PMID: 32963028) J Cutan Med Surg. 2010 Jan-Feb;14(1):19-23. (PMID: 20128986) Int J Mol Sci. 2021 Apr 06;22(7):. (PMID: 33917321) Eur J Clin Pharmacol. 1983;24(1):103-8. (PMID: 6832191) Cochrane Database Syst Rev. 2017 Mar 21;3:CD004454. (PMID: 28321847) Med J Aust. 2020 May;212(9):416-420. (PMID: 32266987) Biomolecules. 2021 Aug 13;11(8):. (PMID: 34439868) Int J Clin Pract. 2006 Jan;60(1):85-92. (PMID: 16409433) JAMA. 2020 Oct 6;324(13):1330-1341. (PMID: 32876694) Lancet Infect Dis. 2020 Jun;20(6):669-677. (PMID: 32240634) Biopharm Drug Dispos. 1987 May-Jun;8(3):205-12. (PMID: 3593899) Intensive Care Med. 2020 May;46(5):846-848. (PMID: 32125452) Nat Rev Immunol. 2020 Oct;20(10):587-588. (PMID: 32778829) Am J Obstet Gynecol. 2018 Jul;219(1):62-74. (PMID: 29630886) Am J Transplant. 2020 Jul;20(7):1859-1863. (PMID: 32181990) BMC Infect Dis. 2021 May 11;21(1):436. (PMID: 33975548) J Ethnopharmacol. 2022 Jan 10;282:114589. (PMID: 34492321) Acta Obstet Gynecol Scand. 1996 Mar;75(3):213-6. (PMID: 8607331) Cochrane Database Syst Rev. 2018 Jun 02;6:CD012629. (PMID: 29859017) J Allergy Clin Immunol. 2007 Nov;120(5 Suppl):S94-138. (PMID: 17983880) JAMA. 2020 Jun 9;323(22):2256-2257. (PMID: 32383733) Aliment Pharmacol Ther. 2015 Sep;42(5):599-606. (PMID: 26096497) Ann Med Surg (Lond). 2020 Dec;60:413-416. (PMID: 33200031) Clin Transl Sci. 2020 Mar;13(2):391-399. (PMID: 31808984) Lancet. 2017 Jul 8;390(10090):169-177. (PMID: 28077232) Front Immunol. 2019 Jul 24;10:1744. (PMID: 31396235) Clin Infect Dis. 2020 Nov 19;71(16):2114-2120. (PMID: 32427279) Emerg Microbes Infect. 2020 Dec;9(1):1869-1877. (PMID: 32795143) J Pharmacokinet Pharmacodyn. 2021 Apr;48(2):261-272. (PMID: 33389521) Lancet Respir Med. 2020 Mar;8(3):267-276. (PMID: 32043986) Int J Mol Sci. 2017 Oct 20;18(10):. (PMID: 29053578) Steroids. 1973 Aug;22(2):193-202. (PMID: 4795381) Pediatr Infect Dis J. 2003 Aug;22(8):721-6. (PMID: 12913774) Br J Clin Pharmacol. 1975 Aug;2(4):327-32. (PMID: 1233992) Genes Dev. 2005 May 1;19(9):1116-27. (PMID: 15879558) Lancet. 2020 Feb 15;395(10223):497-506. (PMID: 31986264) Arch Immunol Ther Exp (Warsz). 2013 Oct;61(5):385-95. (PMID: 23689532) BMJ Open. 2019 Aug 1;9(8):e028511. (PMID: 31375615) Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):183-184. (PMID: 32164084) Lancet. 2020 Feb 15;395(10223):473-475. (PMID: 32043983) PLoS One. 2021 May 25;16(5):e0252057. (PMID: 34033648) Clin Infect Dis. 2021 May 4;72(9):e373-e381. (PMID: 32785710) BMJ. 2020 May 26;369:m1936. (PMID: 32457027) Crit Care Med. 2020 Feb;48(2):e98-e106. (PMID: 31939808) Eur Respir J. 2020 Dec 24;56(6):. (PMID: 32943404) Ann Thorac Med. 2014 Oct;9(4):187-92. (PMID: 25276236) J Biomol Struct Dyn. 2021 Nov;39(18):7017-7034. (PMID: 32851912) J Clin Pharmacol. 2003 Nov;43(11):1216-27. (PMID: 14551176) Diabetes Metab Syndr. 2020 Sep - Oct;14(5):971-978. (PMID: 32610262) Clin Immunol Immunopathol. 1983 Mar;26(3):335-49. (PMID: 6223748) Antimicrob Agents Chemother. 2020 Aug 20;64(9):. (PMID: 32571831) JAMA Intern Med. 2020 Jul 1;180(7):934-943. (PMID: 32167524) Infect Dis Ther. 2020 Dec;9(4):943-952. (PMID: 32986226) Indian J Dermatol Venereol Leprol. 2015 Jan-Feb;81(1):95. (PMID: 25566921) J Pediatr Surg. 2014 Jan;49(1):61-5; discussion 65. (PMID: 24439582) Ann Intern Med. 2015 Oct 6;163(7):519-28. (PMID: 26258555) Lancet. 2020 Feb 15;395(10223):507-513. (PMID: 32007143) Clin Pharmacokinet. 2005;44(1):61-98. (PMID: 15634032) Clin Rheumatol. 2009 Jul;28(7):749-56. (PMID: 19252817) Front Endocrinol (Lausanne). 2016 Apr 19;7:31. (PMID: 27148162) Intensive Care Med. 2017 Dec;43(12):1781-1792. (PMID: 28940017) BMC Pulm Med. 2016 Feb 10;16:29. (PMID: 26864571) Expert Rev Anti Infect Ther. 2011 Jul;9(7):807-22. (PMID: 21810053) Clin Pharmacol Ther. 1979 Aug;26(2):232-9. (PMID: 455892) Open Forum Infect Dis. 2020 Sep 12;7(10):ofaa421. (PMID: 33072814) Immunopharmacology. 1998 Jul;40(1):57-66. (PMID: 9776479) Am J Respir Crit Care Med. 2018 Mar 15;197(6):757-767. (PMID: 29161116) Wien Klin Wochenschr. 2021 Apr;133(7-8):303-311. (PMID: 33534047) J Clin Endocrinol Metab. 1972 Jan;34(1):44-50. (PMID: 5008232) Ann Intern Med. 2001 Aug 21;135(4):248-57. (PMID: 11511139) Clin Pharmacol Ther. 1975 Sep;18(3):330-7. (PMID: 1100302) PLoS One. 2020 Sep 22;15(9):e0239401. (PMID: 32960899) Chin Med J (Engl). 2020 May 5;133(9):1025-1031. (PMID: 32044814) Blood. 2010 Dec 9;116(24):5347-56. (PMID: 20739658) |
| فهرسة مساهمة: | Keywords: COVID-19; corticosteroids; dexamethasone; inflammatory impacts; methylprednisolone; pharmacodynamics; pharmacokinetics |
| تواريخ الأحداث: | Date Created: 20220304 Latest Revision: 20220305 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC8886296 |
| DOI: | 10.3389/fmicb.2022.813358 |
| PMID: | 35242118 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-302X |
|---|---|
| DOI: | 10.3389/fmicb.2022.813358 |